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Mesenchymal stem cells (MSCs) display pleiotropic
functions, which include secretion of soluble factors
with immunosuppressive activity implicated in can-
cer progression. We compared the immunomodula-
tory effects on natural killer (NK) cells of paired intra-
tumor (T)- and adjacent non-tumor tissue (N)-derived
MSCs from patients with squamous cell lung carci-
noma (SCC). We observed that T-MSCs were more
strongly immunosuppressive than N-MSCs and
affected both NK function and phenotype, as defined
byCD56 expression. T-MSCs shifted NK cells toward
the CD56dim phenotype and differentially modulated
CD56bright/dim subset functions. Whereas MSCs
affected both degranulation and activating receptor
expression in the CD56dim subset, they primarily in-
hibited interferon-g production in the CD56bright sub-
set. Pharmacological inhibition of prostaglandin E2
(PGE2) synthesis and, in some MSCs, interleukin-6
(IL-6) activity restored NK function, whereas NK cell
stimulation by PGE2 alone mimicked T-MSC-medi-
ated immunosuppression. Our observations provide
insight into how stromal responses to cancer
dampen NK cell activity in human lung SCC.
INTRODUCTION
Lung cancer is the second most common malignancy and the
leading cancer in terms of lethality worldwide. More than 85%
of cases fall into the non-small-cell lung cancer (NSCLC) class,
which is associated with a predicted 5-year survival of 17.8%
and whose predominant histological subtypes are adenocarci-
noma (50%) and squamous cell carcinoma (SCC) (40%;
Chen et al., 2014). The tumor microenvironment provides
a wide range of resources that support NSCLC progression
(Wood et al., 2014), among which are diverse stromal cells,
including activated mesenchymal stem cells (MSCs) (Bussard
et al., 2016; Raffaghello and Dazzi, 2015).Cell Report
This is an open access article under the CC BY-NAlthough they were initially described in the bone marrow
(BM), MSCs display a broad tissue distribution and are found
in adipose, synovial, and lung tissue as well as in umbilical
cord and peripheral blood (Williams and Hare, 2011). MSCs
are a heterogeneous stromal cell population defined based on
three functional and phenotypic criteria: adherence to plastic;
expression of selected and lack of lineage-specific cell surface
markers; and the capacity to differentiate toward a variety of
mesenchymal lineages (Dominici et al., 2006). Among a plethora
of effector functions, MSCs have been reported to exert immu-
nosuppressive activity after priming by cytokines from a pro-in-
flammatory microenvironment, particularly interferon-g (IFN-g),
tumor necrosis factor a (TNFa), and interleukin-1b (IL-1b) or
through toll-like receptor (TLR) stimulation (Bernardo and Fibbe,
2013; Dumitru et al., 2014; Krampera, 2011). Following activa-
tion, the spectrum of MSC immunosuppressive activity in hu-
mans includes secretion of human leukocyte antigen (HLA-G),
transforming growth factor b (TGFb), prostaglandin E2 (PGE2),
tumor necrosis factor alpha-inducible protein 6 (TNFAIP6/
TSG-6), heme oxygenase 1 (HO-1/HMOX1), IL-10, IL-6, indole-
amine 2,3-dioxygenase 1 (IDO1), hepatocyte growth factor
(HGF), and leukemia inhibitory factor (LIF) as well as pro-
grammed death ligand (PD-L1/2) and Fas ligand (FasL) signaling
(Poggi and Giuliani, 2016; Poggi et al., 2014; Spaggiari and Mor-
etta, 2013; Stagg and Galipeau, 2013; Turley et al., 2015; Uccelli
et al., 2006; Le Blanc and Davies, 2015). The immunosuppres-
sive effects of MSCs require proximity to their target cells, which
include T and B lymphocytes as well as natural killer (NK) cells
(Aggarwal and Pittenger, 2005; Uccelli et al., 2008).
As a first line of defense against tumors and pathogens, NK
cells patrol tissues and can exert antitumor immunosurveillance
by secreting cytokines, including IFN-g, TNFa, and IL-10, and
releasing cytotoxic granules whose contents kill tumor cells.
Not surprisingly, NK cell infiltration of tumor tissue correlates
with better prognosis in diverse cancer types, including lung car-
cinomas (Platonova et al., 2011; Villegas et al., 2002), and lowNK
cell activity is associated with increased cancer risk in adults
(Imai et al., 2000). NK cell detection of and response to target
cells are regulated by cell surface activating and inhibitory recep-
tors. Activation of NK cells therefore requires integration of sig-
nals from their target cells that may be subject to modulations 20, 2891–2905, September 19, 2017 ª 2017 The Author(s). 2891
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Adipocytes
Oil Red O
Control N-MSC1 (p4) T-MSC1 (p5)
Osteocytes
von Kossa
Chondrocytes
Alcian bue
C
D N-MSC1 (p5) T-MSC1 (p5)
H&E
α−SMA
Vimentin
MSC markers
Negative control
N-MSC1 (p7) T-MSC1 (p3)
B
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Tumor type
Moderately to
poorly
dif ferentiated
invasive SCC
Poorly
dif ferentiated
SCC
Moderately
dif ferentiated
keratinizing
SCC, partially
sarcomatoid
Poorly
dif ferentiated
SCC,
basaloid
subtype
Moderately
dif ferentiated
SCC, with
focal
keratinization
TNM pT2b N0 (0/14)Mx
pT2a pN0
(0/20) R0
pT3 pN9 (0/35)
Mx R0
pT2a pN0 (0/8) pT2a pN0 (0/7)
pL0 R0
Sex Female Female Male Male Male
Age 79 64 70 83 74
Smoking
history Yes Yes Yes Yes Yes
Neoadjuvant No No No No No
A
SCC: squamous cell carcinoma; p: pathological classification; T: primary tumor; N: node; M: metastasis; 
X: not assessed histologically; R: residual tumor; L: lymphatic invasion. pTNM classification following the
criteria of «The TNM Classification of Malignant Tumours, 8th Edition, UICC», edited by Prof. James Brierle, 
Wiley Blackwell, 2016.
100μm
100μm
Figure 1. Clinical Data and MSC Characterization
(A) Clinical data related to the five patients. See also Table S1.
(B–D) Characterization of N- and T-MSCs from one representative patient. (B)
Expression of CD90, CD105, CD73, and lineage (Lin: anti-CD14, -CD20,
2892 Cell Reports 20, 2891–2905, September 19, 2017by diverse cell types, including MSCs (Moretta et al., 2001;
Spaggiari et al., 2008; Vivier et al., 2008).
NK cell function correlates with CD56 expression, where high
(CD56bright) and low (CD56dim) expression are associated with
elevated cytokine production and high degranulation potential,
respectively (Caligiuri, 2008; Cooper et al., 2001; Lanier et al.,
1986). NK cells are found in the stroma of human lung tumors
(Jin et al., 2014), where they primarily display a CD56dim pheno-
type, low expression of multiple activating receptors (Platonova
et al., 2011; Vitale et al., 2014), and reduced function (Cremer
et al., 2012; Gillard-Bocquet et al., 2013; Hodge et al., 2014;
Pross and Lotzova´, 1993).
Bone-marrow-derived MSCs (BM-MSCs) can inhibit NK cell
proliferation, cytotoxicity, and cytokine production by secreting
IDO1, TGFb, HLA-G, and PGE2 (Casado et al., 2013; Krampera
et al., 2006; Rasmusson et al., 2003; Spaggiari et al., 2008). How-
ever, they can also be lysed by activated NK cells, depending on
their expression of activating NK receptor ligands, including
MHC class I polypeptide-related sequence (MICA, B), UL16
binding proteins (ULBPs), CD112, and CD155 (Poggi et al.,
2005; Spaggiari et al., 2006, 2008). Most of our understanding
of the functional MSC-NK cell relationship stems from experi-
ments using normal BM-MSCs, peripheral blood NK cells, and
tumor cell lines. In tumors, however, MSCsmay become constit-
uents of the tumor niche and display distinct features from those
of MSCs derived from healthy tissues or the BM (DelaRosa et al.,
2012; Di Trapani et al., 2013; Gottschling et al., 2013; Johann
et al., 2010; Liu et al., 2014).
Here, we provide insight into the effect of tumor-associated
MSCsonNKcell activitybycomparing the immunomodulatoryac-
tivity toward freshly isolatedNKcells fromhealthydonorsofpaired
samples ofMSCs isolated from tumor tissue (T-MSCs) andnormal
adjacent lung tissue (N-MSCs) of patientswith squamouscell lung
carcinoma. We observed marked differences between T- and
N-MSCs, from their phenotype to their immunosuppressive
function. Despite the ability of MSCs to secrete a variety of medi-
ators with immunosuppressive effects, T-MSCs could mediate
inhibition ofNKcell functionprimarily throughPGE2.Our observa-
tions provide insight into how stromal responses to cancer growth
blunt NK cell activity in human lung SCC.RESULTS
Characterization of MSCs Isolated from Patients with
Lung SCC
Stromal cells were isolated from dissociated primary lung SCC
(Figure 1A) as well as from adjacent non-tumor tissue from five
patients and verified for functional and phenotypic MSC features
as defined by the International Society for Cellular Therapy
(ISCT) (Dominici et al., 2006). Accordingly, both tumor and-CD34, and -CD45 antibody cocktail) markers by flow cytometry is shown. Cell
passage (p) is shown in brackets. Cells stained with isotype-matched anti-
bodies provided the negative control. (C) Adipogenic (Oil red O), osteogenic
(Von Kossa), and chondrogenic (Alcian blue) MSC differentiation potentials are
shown. Cells cultured in standard medium provided the control condition. The
scale bar represents 100 mm. (D) H&E, a-SMA, and vimentin IHC stainings are
shown. The scale bar represents 100 mm.
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tumor-free lung-tissue-derived stromal cells, which we selected
for our study, were adherent to plastic under standard culture
conditions; expressed comparable levels of CD105, CD73, and
CD90 and lacked expression of lineage markers (Figure 1B);
and underwent differentiation to osteocytes, adipocytes, and
chondrocytes in vitro in response to appropriate stimulation (Fig-
ure 1C). Because of the uncertainty as to the distinction between
tumor-associated MSCs and myofibroblasts, often termed can-
cer-associated fibroblasts (CAFs) (Kalluri, 2016), we assessed
the expression of the intermediate filament vimentin, a marker
of mesenchymal cells, and a-smooth muscle actin (a-SMA), a
hallmark of myofibroblasts (Desmoulie`re et al., 2004) in our stro-
mal cells. Immunohistochemical (IHC) analysis using specific
anti-vimentin and anti-a-SMA antibodies revealed that, as
expected, the majority of MSCs expressed vimentin but dis-
played undetectable levels of a-SMA (Figure 1D).
Immunophenotype of Tumor-Infiltrating Cells and
Primary Cancer Cell Characterization
Untreated, surgically removed primary lung tumors from five
patients with a smoking history were subjected to histological
analysis and diagnosed as moderately to poorly differentiated,
invasive SCC (TNM pT2-pT3; Figure 1A; Table S1). Immune
cell tumor infiltrates were assessed by immunostaining of tissue
sections from four patients for CD3, CD4, CD8, CD20, CD68
KP1, Granzyme B, CD56, PD-L1, PD1, and FoxP3 (Table S1)
and by flow cytometry of cells from three of the tumors (patients
1, 2, and 5). NK cells constituted less than 1% of the total CD45+
cell infiltrate in all three tumors (0.2% of CD45+ cells for patient 1,
0.59% for patient 2, and 0.55% for patient 5). The relative abun-
dance of T cells (CD4+, CD8+, and FoxP3+CD25+ T reg cells),
B cells, and myeloid cells was variable among the samples,
reflecting IHC staining (Figure S1; Table S1).
Primary cancer cells (PCC) from three of the patients (patients
2, 3, and 4) were obtained by culturing single cells from the tumor
bulk in ultra-low attachment flasks and in knockout (KO) mediumFigure 2. T-MSCs Are More Immunosuppressive Than N-MSCs Towar
(A) Schematic representation of direct and indirect co-culture experiments.
(B, C, D, and F) NK cell activation (percentages of CD107a and intracellular IFN-g
as assessed by flow cytometry. Results were normalized to those of NK cells
(the control condition is represented by the horizontal dashed line). Results show
(B) Direct co-cultures. Graphs plot individual values of 8 independent experimen
licates]; MSC2 [n = 2]; MSC3 [n = 6]; MSC4 [n = 2]; MSC5 [n = 1]) and 3 experime
MSC4 [n = 1]).
(C) Indirect co-cultures. Two experiments were done with K562 cells (two NK cell
PCC (one NK cell donor; MSC1 [n = 1]; MSC3 [n = 1]).
(D) Comparison of the effects of BM-MSCs to those of lung tissueMSCs. Graphs p
(two different NK cell donors; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]; BM-MSC
[n = 1]; MSC3 [n = 1]; MSC4 [n = 1]; BM-MSC [n = 3]).
(E) IFN-g secretion (pg/mL) by NK cells co-cultured with N- (blue bar) and T-MSCs
right panel). IFN-g secretion by NK cells cultured alone is shown in green. Light co
after activation. Mean values ± SEM for 3 experiments with K562 as target cells (th
one experiment with PCC as target cells (one single NK cell donor; MSC1 [n = 1
(F) Percentages of IFN-g+/CD107a+/ NK cell subpopulations after 4 days of co-
and MSCs from one patient (MSC3; n = 6).
(G) Representative flow density dot plots showing expression of IFN-g and CD107
NK cell donor; MSC3).
Statistical significance was determined by Wilcoxon matched-pairs signed ran
correction (D; * indicates significance at p < 0.05; **p < 0.01; ns, not significant).
2894 Cell Reports 20, 2891–2905, September 19, 2017supplemented with growth factors. Cells were selected for their
ability to form spheres in culture and tested for tumorigenicity
following injection beneath the kidney capsule of NOD-SCID
common g-chain knock out (NSG) mice. We then addressed
the potential of the PCC to become NK target cells by assessing
their expression of NK activating receptor ligands (Figures S2A
and S2B) and HLA class I molecules (Figure S2C) in comparison
to that of the K562 leukemia cell line, a classical NK target.
Primary cells from lung SCC displayed lower expression of
several NK cell ligands than the K562 cell line, including CD112
(NECTIN2), CD155 (PVR), and ULBP1. In contrast, expression
of the NKG2D ligands MICA and MICB was higher than that of
other ligands in PCC (Figure S2A) and comparable to their
expression in K562 cells (Figure S2B). MICA and MICB are
involved in NK cell activation by interacting with NKG2D (Jamie-
son et al., 2002), on the one hand, and in NK exhaustion upon
extended stimulation on the other (Groh et al., 2002; Chretien
et al., 2014; Oppenheim et al., 2005). HLA class I expression
tended to increase over time in PCC co-cultured with NK cells
(Figures S2Ci and S2Cii), which may provide a mechanism of
resistance to NK cell killing. Although PCC appeared to display
a phenotype that is less prone to induce NK activation than
that of K562 cells, they were nevertheless able to stimulate NK
cell degranulation at different effector:target ratios (Figure S2D).
Thus, primary lung SCC cells are sensitive to NK-mediated
immunosurveillance.
T-MSCs Suppress the NK Cell Response to K562 and
Primary SCC Cells More Strongly Than N-MSCs
The effect of T- and N-MSCs on NK cell function was investi-
gated in direct and indirect (Transwell) co-culture conditions
(Figure 2A). Freshly isolated NK cells were cultured with T- and
N-MSCs for 4 days, following which their activation by tumor
cells was assessed in a 4-hr assay. NK cells from different
donors displayed variable activation in response to K562 cells
and PCC (Figure S3A). Nevertheless, in direct co-culture,d the NK Response to K562 and PCC
-positive cells) by K562 or PCC cells following N-, T-, and BM-MSC co-culture,
cultured without MSCs for the same duration and activated by target cells
the mean ± SEM.
ts with K562 cells (eight different NK cell donors; MSC1 [n = 3 biological rep-
nts with PCC (three NK cell donors; MSC1 [n = 1]; MSC2 [n = 1]; MSC3 [n = 2];
donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]) and one with
lot individual values of two experiments in direct MSC-NK co-culture with K562
[n = 2]) and 2 experiments with PCC (PCC2, 3, and 4; two NK cell donors; MSC2
(red bar) before and after activation by tumor cells (K562, left panel, and PCC,
lor bars, basal NK cell secretion (without tumor cells); dark color bars, secretion
ree NK cell donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 3]; MSC4 [n = 1]) and
] and 3 [n = 1]) are shown.
culture with MSCs in 5 independent experiments using NK cells from 5 donors
a by K562-activated NK cells in direct co-culture with and without MSCs (single
k test (pairing on MSC patient; B, C, and F) or unpaired t test with Welch’s
See also Figure S3.
T-MSCs were consistently and significantly more immunosup-
pressive than N-MSCs toward NK cells exposed to K562 cells,
as assessed by IFN-g production and CD107a (lysosomal-asso-
ciated membrane protein-1) expression, commonly used as a
marker of degranulation (Alter et al., 2004; Figures 2B and
S3Bi). Following activation by PCC, production of IFN-g as well
as degranulation were slightly, but not significantly, more
reduced in the presence of T-MSCs than in that of N-MSCs (Fig-
ures 2B and S3Bi). T-MSCs also exerted stronger suppression of
IFN-g production than of degranulation (Figure 2B).
In indirect co-culture, T-MSCs were less immunosuppres-
sive than in direct co-culture and their inhibition of NK cell
IFN-g production and degranulation was comparable to that
of N-MSCs (Figures 2C and S3Bii). In contrast to direct co-cul-
ture, NK cell production of IFN-g in response to PCC was more
strongly inhibited by N- than by T-MSCs. Thus, the robust
immunosuppressive activity of T-MSCs toward NK cells ap-
peared to be contact dependent and effective in the presence
of both K562 cells and PCC. Because the immunosuppressive
potential of MSCs has thus far been studied mainly using
BM-MSCs, we included one sample isolated from an adult
healthy donor as a reference for MSC-mediated NK inhibition.
Bone marrow MSCs displayed strong inhibitory activity toward
both IFN-g production and degranulation by NK cells (Fig-
ure 2D) that was more closely reminiscent of T- than of
N-MSCs.
Inhibition by MSCs (T-MSC > N-MSC) of intracellular IFN-g
production was reflected at the secretory level (Figure 2E, dark
bars). Moreover, the inhibition was observed even before NK
cell activation by K562 cells and PCC (Figure 2E, light bars).
Similar to IFN-g secretion, TNFa secretion by NK cells after acti-
vation by K562 cells was inhibited in the presence of MSCs and
more strongly so in that of T- than of N-MSCs. Although the inhi-
bition was less marked when K562 cells were substituted by
PCC, the tendency was similar (Figure S3C).
We next interrogated the response to T- and N-MSCs of the
different functional NK cell subpopulations, including IFN-
g+CD107a+ double-positive, IFN-g+CD107a single-positive,
and IFN-gCD107a+ single-positive cells (Figures 2F, 2G, and
S3D). The strongest and most selective inhibition by T-MSCs
was observed in the NK double-positive subpopulation. The
IFN-g+CD107a single-positive subpopulation was equally
inhibited by N- and T-MSCs, whereas the IFN-gCD107a+ sin-
gle-positive NK subpopulation was virtually unaffected (Fig-
ure 2F). Thus, the NK subpopulations that are the most strongly
inhibited by MSCs, particularly in direct co-culture, are those
capable of secreting IFN-g (Figures 2F and 2G).
T-MSCs Downregulate NK-Cell-Activating Receptors
and Induce the CD56dim NK Cell Phenotype
To understand how MSCs downregulate NK cell function, we
interrogated NK receptor modulation in the presence of T- and
N-MSCs. MSCs (T-MSC > N-MSC) inhibited cell surface expres-
sion of the NK receptors NKp44, NKp30, NKG2D, DNAM-I, and
NKG2A (Figure 3Ai). Differences between the inhibitory effects of
N- and T-MSCs were significant for NKG2D, DNAM-I, and
NKG2A receptors. Interestingly, their expression was affected
only in direct contact with MSCs (Figure 3Ai), with the exceptionof NKp44, whose expression was partially inhibited in indirect
co-culture (Figure 3Aii).
Surprisingly, we observed marked changes in the
CD56bright/dim ratios of NK subpopulations in response to
MSCs. In the absence of MSCs and after 4 days of exposure
to IL-2, NK cells were predominantly CD56bright. However, an
inversion in the CD56bright/dim NK cell ratio was observed in direct
co-culture with MSCs (Figures 3Bi and 3C) that was largely
contact dependent (Figures 3B and 3C).
CD56bright and CD56dim NK Subpopulation Function Is
Differentially Modulated by MSCs
In functional assays where NK cells are activated by tumor cells,
the presence of MSCs, particularly T-MSCs, also tipped the
balance toward the CD56dim NK phenotype in a contact-depen-
dent manner (Figure 4A). Functional comparison revealed that
BM-MSCs were more closely related to T-MSCs than to
N-MSCs, as demonstrated by their robust induction of the
CD56dim NK subset after activation by K562 cells (Figure 4Bi)
and PCC (Figure 4Bii).
Interestingly, inhibition of NK cell function exerted by MSCs
differed between the CD56dim/bright subpopulations. In control
conditions (NK cells cultured with K562 cells alone), the
CD56bright NK cell subset (Figure 4C, first line), associated with
elevated cytokine production, was dominant. Upon introduction
of MSCs (Figure 4C, lines 2 and 3), the bulk NK cell population
decreased its cytokine production and degranulation capacity.
However, because the presence ofMSCs increased the CD56dim
subpopulation, which was associated with degranulation, the
change in function of the total NK cell populationmostly reflected
functional inhibition of the CD56dim subset. Thus, MSC-medi-
ated IFN-g inhibition occurred predominantly in the CD56bright
subpopulation, whereas NK degranulation was inhibited by
MSCs in the CD56dim subtype. Inhibition of both functions,
particularly cytokine production, was largely contact dependent
(Figure 4C). The total NK cell population indirectly co-cultured
with MSCs was mainly composed of CD56bright cells, prone to
cytokine secretion and comparable to NK cells activated by
tumor cells without MSCs.
Modulation of NK receptors also differed between the
CD56dim and CD56bright NK subsets. Thus, downregulation of
NKp44, NKp30, NKG2D, and DNAM-I receptor expression
occurred in the CD56dim subpopulation, appeared to be highly
contact dependent, and was more pronounced in the presence
of T-MSCs than in that of N-MSCs (Figure 4D). In indirect co-cul-
ture, only NKp44 receptor expression was mildly inhibited,
whereas NKG2D receptor expression was slightly increased. In
the CD56bright subset, only NKG2D expression was slightly
decreased in direct co-culture with MSCs. With this exception,
receptor expression in CD56bright NK cells remained virtually
unaffected by direct or indirect co-cultures with MSCs.
Inhibition of NK cell activating receptors (NKp44, NKp30,
NKG2D, and DNAM-I) may provide the mechanism that under-
lies MSC-mediated dysfunction of CD56dim NK cells. In contrast,
inhibition of cytokine production in the CD56bright subset was not
associated with major changes in receptor expression, except
for mild NKG2D downregulation in direct co-culture with MSCs
(Figure 4D). We therefore interrogated the mechanisms involvedCell Reports 20, 2891–2905, September 19, 2017 2895
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Figure 3. The NK Cell Phenotype Is Strongly Modulated by Direct
Co-culture with N- and T-MSCs
(A and B) NK phenotype as assessed by flow cytometry after direct (i) and
indirect (ii) co-cultures with N- or T-MSCs, normalized to control conditions
(NK cells alone, horizontal dashed line). Mean values ± SEM are shown.
(A) Expression of NK cell receptors is shown. (i) Data from 4 experiments are
shown (four NK cell donors; MSC1 [n = 2]; MSC2 [n = 2]; MSC3 [n = 2]; MSC4
[n = 1]; MSC5 [n = 1]). (ii) Results from 2 experiments are shown (two NK cell
donors; MSC1 [n = 2]; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n = 1]). Data were
analyzed using Wilcoxon matched-pairs signed rank test. (B) Percentages of
CD56bright and CD56dim NK subpopulations in control conditions (NK cultured
alone, green bar) and in co-culture with N- and T-MSCs are shown. Light tones
depict the CD56dim NK subset, dark tones the CD56bright subset. (i) Results
from 4 experiments are shown (four NK cell donors; MSC1 [n = 6]; MSC2
[n = 2]; MSC3 [n = 8]; MSC4 [n = 2]). (ii) Data from 2 experiments are shown (two
NK cell donors; MSC1 [n = 6]; MSC2 [n = 3]; MSC3 [n = 6]; MSC4 [n = 3]).
(C) Representative flow smooth contour plots (with outliers) showing CD16 and
CD56 expression by NK cells in direct and indirect co-cultures with and
without MSCs (single NK cell donor; MSC3).
2896 Cell Reports 20, 2891–2905, September 19, 2017in MSC-induced suppression of cytokine production in the
CD56bright NK subset.
Expression of Immunosuppressive Mediators in T- and
N-MSCs
First, we addressed the expression of genes implicated in
immune regulation in T-, N-, and BM-MSCs, including IDO1,
IL10, TGFB1, TNFAIP6 (TSG6), HMOX1, HLAG, IL6, and
PTGS2 (COX-2; Figures 5A and S4A). Whereas IDO1, IL10, and
HLAG transcripts were almost undetectable at day 0 in culture
(data not shown), IL6 and PTGS2 were expressed at variable
levels in T- and N-MSCs from different patients (Figures 5A
and S4A). Expression of some of these genes differed between
BM-MSCs and lung tissue MSCs (Figure S4A). Thus, IL6 expres-
sion in BM-MSCs was lower than in most T-MSCs and TNFAIP6
was almost undetectable (Figure S4A). Conversely, TGFB1 and
PTGS2 were more highly expressed in BM-MSCs than in
T-MSCs, with the exception of T-MSC1 (Figure S4A). T-MSCs
from patients 2 and 5 expressed higher levels of IL6 than their
non-tumor-tissue-derived counterparts, whereas PTGS2
expression was comparable in the twoMSC subsets (Figure 5A).
However, T- and N-MSCs displayed distinct secretion levels of
IL-6 and PGE2 after 4 days in culture (even though the statistical
values for the latter were not significant; Figure 5B), which could
explain, at least in part, the differential impairment by the MSC
subsets of NK cell function. Expression of IL6 and PTGS2 by
T-MSCs increased over time in culture and was strongly induced
by the presence of NK cells, whereas expression of TGFB1
remained constant (Figure 5C). In co-culture with tumor-acti-
vated NK cells, MSCs secreted high levels of IL-6, TGFb1, and
HGF, but of the three cytokines, IL-6 was the most differentially
secreted between T- and N-MSCs and more so in the presence
of PCC-activated NK cells (Figure S4B). Comparison between
BM- and lung tissue MSC secretion of IL-6 and PGE2 (Fig-
ure S4C) in direct co-culture with NK cells and following activa-
tion by tumor cells revealed lower secretion of IL-6 by BM-MSCs
than by T-MSCs but comparable secretion of PGE2 by the two
MSC populations. In addition, BM-MSCs bore similarities to
lung tissue MSCs for MICA and TLR3 expression but also a
distinct profile with higher TLR4 and lower CD274, NECTIN2,
DC
A  B
(legend on next page)
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and PVR expression (Figure S4D). MSCs expressed low levels of
NK-activating receptor ligands, except for the DNAM-I ligand
PVR (CD155; Figures S4D and S4E).
IL-6 and PGE2 Are Implicated in T-MSC-Mediated
Inhibition of NK Cell Function
Neutralization of IL-6 with a specific antibody (MAB206) and
inhibition of COX-2 using a specific inhibitor (NS-398) were
each partially effective in restoring NK function that had been
suppressed by MSCs. However, the efficacy of the inhibitors
appeared to be highly individual patient MSC dependent.
COX-2 inhibition was the most effective in restoring NK cell func-
tion, whereas IL-6 had more heterogeneous effects. Analysis of
co-culture supernatants demonstrated the level of inhibition
reached using the inhibitors (Figure S5A). Interestingly, IL-6 inhi-
bition increased PGE2 secretion (Figure S5Aiii).
Three experiments highlighted the heterogeneity of immuno-
modulatory mechanisms used by primary cells. In experiments
using patient 2 MSCs, neutralization of IL-6 with antibody
partially restored NK cell function, asmeasured by IFN-g expres-
sion in response to K562 cells (Figure 6Ai). Similarly, inhibition of
PGE2 synthesis using the COX-2 inhibitor NS-398 resulted in
partial reversion of NK loss of IFN-g expression induced by
MSCs (Figure 6Ai). In contrast, neither inhibitor had a marked
effect on NK cell degranulation (Figure S5Bi). Interestingly,
rescue of NK cell cytokine expression resulting from inhibiting
IL-6 and COX-2 function correlated with restoration of the
CD56bright NK cell phenotype (Figures 6Aii and 6Aiii).
Surprisingly, in experiments with patient 5 MSCs (n = 2), addi-
tion of anti-IL-6 antibody did not restore NK cell function,
whereas COX-2 inhibition partially reversed MSC-mediated
blockade of IFN-g expression and degranulation (Figures 6Bi
and S5Ci). Nevertheless, COX-2 and IL-6 inhibition appeared
to have a synergistic effect. Partial restoration of both NK cell
cytokine production and degranulation by inhibition of MSC-der-
ived immunosuppressive molecules was significantly correlated
with an increase in the CD56bright NK cell phenotype (Figures
6Bii, 6Biii, and S5Cii).
We next investigated the mechanisms involved in the restora-
tion of NK function and CD56 expression and assessed NK
receptor expression. Addition of IL-6 inhibitor partially restored
NKG2D expression in NK cells cultured with T-MSCs from
patient 2 (Figure 6Ci). However, anti-IL-6 enhanced the inhibition
of NKp30 and DNAM-I expression induced by T-MSCs. COX-2Figure 4. MSC Exert Different Effects on CD56dim and CD56bright NK Su
(A and B) Percentages of CD56dim and CD56bright NK cell subpopulations co-cultu
Light tones, CD56dim NK subset; dark tones, CD56bright subset. Tumor-activate
Results show the mean ± SEM. Statistical significance was determined by 2-way
co-cultures with N- and T-MSCs after 4 hr activation by K562 cells are shown. Da
(MSC1-4) and a single NK cell donor. (B) Direct co-cultures with N-MSCs, T-MSCs
representative of two experiments with pooled MSCs from 3 patients (MSC2-4), o
experiments are shown (two NK cell donors; MSC2 [n = 1]; MSC3 [n = 2]; MSC4 [n
shown (two NK cell donors; MSC2 [n = 1]; MSC3 [n = 1]; MSC4 [n = 1]; BM-MSC
(C) Representative dot plots showing the percentages of IFN-g+ and CD107a+ cell
direct and indirect co-cultures with MSCs from patient 2 and activation by K562
(D) Modulation of NK receptor expression in CD56bright and CD56dim subsets i
(NK cultured alone). Results show the mean ± SEM for a single experiment (si
determined by 2-way ANOVA followed by Dunnett’s multiple comparisons test w
2898 Cell Reports 20, 2891–2905, September 19, 2017inhibition increased NKp30 and NKp44 expression slightly and
NKG2D expression more strongly. Neutralization of IL-6 from
patient 5 MSCs had the same effect on NKG2D and NKp30 as
its neutralization in patient 2 MSCs, increasing and decreasing
their expression, respectively (Figure 6Cii). COX-2 inhibition
partially restored NKp44, NKG2D, and NKp30 expression that
had been downregulated by T-MSCs (Figure 6Cii). Combination
of anti-IL-6 and the COX-2 inhibitor was comparable to the effect
of the COX-2 inhibitor alone. Hence, COX-2 inhibitor administra-
tion to MSCs from both patients was effective in at least partially
restoring IFN-g production and NK receptor (NKG2D, NKp30,
and NKp44) expression, whereas anti-IL-6 effects were patient
MSC dependent.
We also assessed NK cell expression of CD25 (IL-2Ra) in
co-cultures with MSCs, which was expressed by a small per-
centage of NK cells. In the presence of T-MSCs, CD25 was
strongly downregulated, and its expression was partially and
completely restored by anti-IL-6 antibody and COX-2 inhibitor,
respectively (Figure 6D).
NK Stimulation with PGE2Mimics T-MSC-Mediated IFN-
g Immunosuppression
To confirm the importance of MSC-mediated PGE2 secretion in
NK cell inhibition, we stimulated NK cells with PGE2 in the
absence of MSCs (donor 14 NK cells) at doses comparable to
those secreted by T-MSCs in the presence of NK cells. PGE2
inhibited cytokine production by NK cells stimulated by K562
cells to a level comparable to that observed in T-MSC co-cul-
tures (Figure 7A). In contrast, IL-6 stimulation did not affect NK
function nor did it display synergy with PGE2 (Figure 7A). NK
degranulation was unchanged after stimulation by PGE2, IL-6,
or both, suggesting a role for PGE2 predominantly in the inhibi-
tion of cytokine production. Moreover, addition of PGE2 to NK
cells increased the CD56dim subpopulation, as did the presence
of T-MSCs (Figure 7B). Finally, stimulation with PGE2 alone was
sufficient to reproduce the downregulation of NK receptors
induced by T-MSCs (Figure 7C).
DISCUSSION
Using paired samples of primary MSCs isolated from lung SCC
and adjacent tumor-free tissue, we showed that tumor-associ-
ated MSCs are more strongly immunosuppressive toward NK
cells than their tumor-free tissue-derived counterparts, exertingbsets
red with MSCs after 4 hr activation by tumor cells, assessed by flow cytometry.
d NK cells cultured in the absence of MSCs provided a control (green bars).
ANOVA followed by Tukey’s multiple comparisons test. (A) Direct and indirect
ta are representative of a single experiment with pooled MSCs from 4 patients
, and BM-MSCs after 4 hr activation by K562 (i) or PCC cells (ii) are shown. Data
ne donor of BM-MSCs, and two NK cell donors are shown. (i) Results from two
= 1]; BM-MSC [n = 2]). (ii) Data from two experiments with PCC2, 3, and 4 are
[n = 2]).
s in the total NK cell population and in the CD56bright and CD56dim subsets after
cells.
n direct and indirect co-cultures with MSCs compared to control conditions
ngle NK cell donor; MSC1 [n = 1] and 3 [n = 1]). Statistical significance was
ith NK cells alone set as the control.
A  
C
B
Figure 5. Differential Expression of Immune-Modulating Mediators
by T- and N-MSCs
(A) Relative gene expression of IL6 and PTGS2 by N- and T-MSCs in the basal
state (day 0 of co-culture) as assessed by qPCR and shown as a fold change in
expression (N-MSC2 expression set as the control condition). Data are
representative of four experiments (four NK cell donors; MSC2, 3, and 5), and
results show the mean ± SEM.
(B) IL-6 and PGE2 secretion (pg/mL) by MSCs after 4 days in culture alone.
Results show the mean ± SEM: MSC1, 2, 3, and 5 for IL-6 and MSC2 and 5 for
PGE2. Statistical significance was determined by Wilcoxon matched-pairs
signed rank test (* indicates significance at p < 0.05; **p < 0.01).
(C) Relative gene expression of IL6, PTGS2, and TGFB1 by T-MSCs collected
at the indicated time points with and without direct co-culture with NK cells
(four NK cell donors; MSC2, 3, and 5). Results show fold change in gene
expression compared to T-MSCs at day 0. Statistical significance was
determined by 2-way ANOVA with Tukey’s multiple comparisons test.
See also Figure S4.stronger inhibition of NK cell IFN-g secretion and degranulation
in response to K562 and primary cancer cells. Functionally,
T-MSCs were more closely related to BM-MSCs than
N-MSCs. As two key functions of BM-MSCs are to participate
in building a hematopoietic stem cell (HSC) niche and to protect
HSCs from injury bymediators of inflammation and inflammatory
effector cells, they must display potent immunosuppressive
properties (Sotiropoulou et al., 2006; Spaggiari and Moretta,2013; Spaggiari et al., 2008). In quiescent tissues, in the absence
of inflammatory stimuli, MSCsmay decrease or even temporarily
lose their immunosuppressive features. However, in a tumor
microenvironment, which mimics tissue repair and contains a
vast array of cytokines derived from inflammatory, tumor, and
activated stromal cells, MSCs may regain their full immunosup-
pressive potential and resemble their BM counterparts. The
immunosuppressive mechanisms, as illustrated by the type
and quantity of immunosuppressive cytokines produced and
the level of NK cell receptor ligands expressed, may differ be-
tween BM- and T-MSCs, possibly as a function of the type of
stimulatory microenvironment to which the cells are exposed.
MSCs, particularly T-MSCs, displayed markedly different
degrees of inhibition of functional NK cell subpopulations, pre-
dominantly inhibiting NK cell subsets that produce IFN-g.
Because IFN-g plays a prominent role in tumor rejection by
preventing tumor stroma formation and tumor-induced angio-
genesis (Zaidi and Merlino, 2011), as well as by activating the
immune system, inhibition of its production by T-MSCs may
be highly relevant toward facilitating tumor progression. Consis-
tent with this notion, recent observations suggest that the
predominant activity of NK cell subsets recruited to lung cancer
is IFN-g production rather than direct cancer cell killing (Carrega
and Ferlazzo, 2017).
In addition to their production of IFN-g, the activating receptor
expression profile of NK cells was significantly affected by
MSCs, with downregulation of NKp44, NKp30, NKG2D,
DNAM-I, and NKG2A. MSCs also induced an inversion in the
CD56bright/dim NK cell ratio in favor of the CD56dim phenotype.
These effects were more pronounced in response to T-MSCs
than to N-MSCs and, just like inhibition of IFN-g production,
were contact dependent. Consistent with these observations, in-
tratumoral NK cells in human lung cancer display low expression
of NKp30, CD56, NKG2D, and DNAM-I (Platonova et al., 2011;
Esendagli et al., 2008; Levi et al., 2015).
The observed shift toward the CD56dim NK cell phenotype
after exposure to MSCs is consistent with low expression of
CD56 by NK cells in vivo (Esendagli et al., 2008; Platonova
et al., 2011; Levi et al., 2015) and selective inhibition of the
CD56bright subtype rather than expansion of the CD56dim sub-
population (Sotiropoulou et al., 2006). Following IL-2 stimulation,
NK cells acquire a CD56bright phenotype, which correlates with
an activated state of the cells in vitro. The CD56dim phenotype
observed in the presence of MSCs therefore seems to reflect a
decrease in NK cell activation, as suggested by our functional
assays and by the reduced NK cell expression of IL-2Ra
following T-MSC co-culture.
CD56dim and CD56bright NK cell functions were differentially
modulated by MSCs. With the exception of NKG2D, T-MSCs
downregulated activating receptor expression exclusively in
the CD56dim NK cell subset, where they also inhibited degranu-
lation. In contrast, T-MSCs inhibited IFN-g production in
CD56bright NK cells where no obvious receptor expression
changes occurred (except for the mild downregulation of
NKG2D). Distinct mechanisms may therefore underlie T-MSC-
mediated inhibition of cytokine production by CD56bright and
degranulation of CD56dim NK cells, with the possible implication
of NKG2D in both functions of the two NK subsets.Cell Reports 20, 2891–2905, September 19, 2017 2899
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Figure 6. Targeting T-MSC-Derived Immunosuppressive Mediators Rescues NK Cell Activity
Data were analyzed by flow cytometry, and results show mean values ± SEM.
(A) Results are from one rescue experiment with a single NK cell donor and MSCs from patient 2.
(legend continued on next page)
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Marked differences in expression and secretion of IL-6 and
PGE2 by N- and T-MSCs suggested that both mediators may
be implicated in T-MSC-mediated immunosuppression. Inter-
leukin-6 and COX-2 inhibitors revealed that T-MSCs rely on
PGE2 to mediate much of their immunosuppressive effect.
Accordingly, addition of COX-2 inhibitor to MSC-NK cell
co-cultures partially restored NK cell IFN-g expression, the
proportion of CD56bright cells, and NKp30, NKp44, NKG2D,
and IL-2Ra expression. COX-2 inhibition in different experi-
ments and using MSCs from different patients consistently
restored NK function, suggesting that PGE2 secretion provides
an immunosuppressive mechanism common to MSCs, irre-
spective of their origin.
PGE2 Is a Key Mediator of T-MSC-Dependent
Immunosuppression
Bone marrowMSCs have been shown to exert a profound inhib-
itory effect on NK-cell function, outside of the tumor context,
mediated by PGE2, IDO1, and/or TGFb (Sotiropoulou et al.,
2006; Spaggiari and Moretta, 2013; Spaggiari et al., 2008). Our
observations suggest that T-MSCs suppress NK cell function
primarily by PGE2, as neither TGFb nor IDO1 were upregulated
in T-MSCs. Interestingly, plasma PGE2 levels in NSCLC patients
have been found to be elevated compared to healthy subjects
(Hidalgo et al., 2002), and high expression of COX-2 in tumor
sections of NSCLC has been associated with poor prognosis
(Bhooshan et al., 2016; Brown and DuBois, 2004; Khuri et al.,
2001). Stimulation of NK cells with PGE2 alone reproduced all
of the principal effects of T-MSCs, including inhibition of IFN-g
production, the shift toward the CD56dim phenotype, and down-
regulation of NK-cell-activating receptors.
Prostaglandin E2 secretion can occur through an IL-6-depen-
dent mechanism, which has been suggested to provide an anti-
inflammatory mediator in arthritis (Bouffi et al., 2010). Abrogation
of IL-6 increased PGE2 secretion by MSCs, which may consti-
tute a candidate mechanism to explain why the combined inhibi-
tion of both was able to better rescue NK cell function. However,
the implication of IL-6 in MSC-mediated NK cell immunomodu-
lation was variable. Whereas in one patient, IL-6 inhibition
partially restored NK cell function, the same did not hold true
for MSC-inhibited NK cells of another patient. Thus, whereas
PGE2 secretion appeared to be a commonmediator of immuno-
suppression by MSCs from different patients, IL-6 seemed to
provide a more patient-specific immunosuppressive function.
Nevertheless, we identified a novel (possibly context-depen-
dent) role for IL-6 in permitting tumor-subverted MSCs to help(B) Summary of two rescue experiments with MSCs from patient 5 (two NK cell
(A and B) (i) Percentage of IFN-g+ NK cells after activation by K562 cells in the pres
Results are normalized to NK cell activation by K562 cells in the absence of MS
activated CD56bright and CD56dim NK subsets cultured alone or with T-MSCs in
determined by 2-way ANOVA followed by Dunnett’s multiple comparisons test, wi
Correlation between the percentage of CD56bright NK cells and intracellular IFN-g
the Spearman correlation coefficient r, p values are reported, and linear regressi
(C) Percentage of NK receptor expression after 4 days in culture alone (gray ba
inhibitors (light red bar). (i) MSC2 is shown; one NK cell donor. (ii) MSC5 is show
(D) Percentage of IL-2Ra (CD25) expression on NK cells cultured alone (gray bar)
Data are representative of a single experiment with a single NK cell donor and M
See also Figure S5.establish an immunosuppressive microenvironment that impairs
NK cell function.
Taken together, our observations show that, despite the vari-
ability of MSCs (including the patient origin of the cells, the stage
of the tumor from which they were extracted, and the variable
expression of ligands for NK cells) and of donor NK cells (from
14 donors, with variations in the panel of receptors expressed
and response to tumor cells), which may influence NK cell acti-
vation and the degree of inhibition mediated by MSCs,
T-MSCs consistently exert stronger immunosuppression of NK
cells than N-MSCs. They also provide a mechanistic explanation
for differences between the immunomodulatory potential of
T- andN-MSCs and highlight the notion that T-MSCsmay largely
rely on PGE2 and to a lesser extent on IL-6 to exert their immu-
nosuppressive effects. Selection of immunosuppressive media-
tors by T-MSCs may be determined by signals derived from the
tumor cells or from the microenvironment they condition, which
may vary from patient to patient. Efforts to discover drugs that
could affect MSC behavior by blocking their inhibitory effects
may provide promising options to improve anti-tumor NK cell
function.EXPERIMENTAL PROCEDURES
Primary MSC and Tumor Cell Isolation
MSCs
Fresh primary human tumor samples and adjacent macroscopically normal
lung tissue were obtained at surgery from 5 SCC patients at the Centre Hospi-
talier Universitaire Vaudois (CHUV) (Lausanne) with the approval and accord-
ing to the guidelines of the Ethics Committee of the Canton de Vaud (project
authorization no. 131/12). Patients 1–5 were aged 79, 64, 70, 83, and 74,
respectively, at the time of surgery. Patients 1 and 2 were female, and patients
35 were male. Pathologic tumor staging varied among patients from T2a to
T3 and was performed at the CHUV. T-MSCs and N-MSCs were isolated after
tissue disruption (see Supplemental Experimental Procedures) and cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% fetal
calf serum (FCS) (PAN-Biotech), 1% penicillin/streptomycin (PS) (Gibco), 1%
non-essential amino acids (NEAA) (Gibco), and 10 ng/mL platelet-derived
growth factor (PDGF) (Prospec; MSC medium). Cells were used at early pas-
sages for all experiments (below p 7). MSCs were assessed for differentiation
potential (to osteocytic, chondrocytic, and adipocytic lineages) andmembrane
expression of selected markers (see Supplemental Experimental Procedures).
Fresh human BM-MSCs were obtained from a healthy donor (male donor; 78
years old; project authorization no. 131/12) and harvested as described above.
Tumor Cells
From 3 out of 5 patient samples, PCCs were isolated and cultured as spheres
in low-attachment conditions in IMDM supplemented with 20% knockout
serum (Gibco), 1%PS, and 20 ng/mL epidermal growth factor (EGF), fibroblast
growth factor (FGF), and LIF (Prospec). PCCs were assessed by flowdonors).
ence of T-MSCs with or without anti-IL-6-neutralizing antibody and/or NS-398.
Cs, considered to be 100% (horizontal dashed line). (ii) Percentages of K562-
the presence or absence of inhibitors are shown. Statistical significance was
th K562-activated NK cells co-cultured with T-MSCs set as the control (red). (iii)
production in different culture conditions is shown. The statistical test used was
on line with R square for goodness of fit.
r) or with T-MSCs in the absence (dark red bar) or presence of the indicated
n; two NK cell donors.
or in the presence of T-MSCs (red bars) with or without the indicated inhibitors.
SC5.
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Figure 7. NK Stimulation with PGE2 Mimics MSC-Mediated IFN-g
Immunosuppression
Data were assessed by flow cytometry on NK cells from a single donor.
T-MSCs used for co-culture were from patient 5.
(A) Percentages of IFN-g+ (black bar) and CD107a+ NK cells (gray bar) after
activation by K562 cells in different culture conditions: with IL-6, PGE2, a
combination of both, or co-cultured with T-MSCs for 4 days (set as the control
condition, red). Results are normalized to 100% as the level of IFN-g
production and CD107a expression by NK cells activated by K562 cells
(horizontal dashed line).
(B) (i) Percentages of CD56bright and CD56dim NK subsets after activation by
K562 cells under conditions described in (A). (ii) Correlation between the
percentages of CD56bright and IFN-g+ NK cells is shown. The statistical test
used was the Spearman correlation coefficient r, significance determined at
p < 0.05, and linear regression line and significance determined with R square
value.
(C) Percentage of indicated receptor expression on NK cells alone, stimulated
with IL-6, PGE2, or both or co-cultured with T-MSCs.
2902 Cell Reports 20, 2891–2905, September 19, 2017cytometry for HLA-ABC expression (see Supplemental Experimental Proced-
ures). The K562 human leukemia cell line (ATCC no. CCL-243) was cultured in
RPMI1640 supplemented with 10% FCS and 1% PS.
Tumor-Infiltrating Immune Cell Characterization
Immune cell infiltration in the tumor bulk was assessed by IHC on whole-tissue
sections from SCCs of four patients and by flow cytometry of tumor bulk from
three patients after dissociation (see Supplemental Experimental Procedures).
Microscopy
Images were taken with a Nikon Eclipse E800, digital camera DXM1200, at
203 or 403 magnification and at a resolution of 1,280 3 1,024, and analyzed
with the ACT-1 (v.2) software.
NK Cell Isolation and Culture
NK cells were isolated from peripheral blood mononuclear cells derived from
buffy coats obtained from 14 healthy volunteer donors with donor consent
and approval from the Ethics Committee of the Canton de Vaud (project autho-
rization no. P-108). NK cells were cultured in RPMI1640 (Gibco) supplemented
with 10% heat-inactivated human serum (Sigma and Life Technologies),
1% PS, and IL-2 (10 ng/mL; R&D Systems; NK medium; see Supplemental
Experimental Procedures).
Co-culture Experiments
T-MSCs and N-MSCs were plated in 96-well plates 24 hr before co-culture
(0.53 105 cells/well). MSCs were treated with mitomycin C 50 mg/mL (Sigma),
and freshly isolated NK cells (105 cells) were added at 1:2MSC:NK ratio. Media
were supplemented with IL-2 10 ng/mL (R&D). After 4 days of NK-MSC co-cul-
ture in NKmedium, 105 K562 target cells or PCCwere added andmaintained in
co-culture for 4 hr.
Flow Cytometry
See Supplemental Experimental Procedures for more detailed information.
MSC Characterization
Cells were stained with the « human MSC phenotyping kit » (no. 130-095-198;
Miltenyi Biotec) according to the manufacturer’s protocol.
NK Phenotype
Before and after 4 days of co-culture with MSCs, the NK cell phenotype was
assessed using anti-NKp30 (phycoerythrin [PE]; no. 558407; BD Biosciences;
1:50), -NKG2D (antigen-presenting cell [APC]; no. 562064; BD Biosciences;
1:10), -NKG2A (fluorescein isothiocyanate [FITC]; no. 130-098-817; Miltenyi;
1:20), -NKp44 (PE; no. 558563, BD Biosciences; 1:15), -DNAM-I (PE; no.
130-100-461; Miltenyi; 1:20), and -CD25 (APC; no. 555434; BD Biosciences;
1:10) antibodies among CD45+CD3CD56+CD16+/ cells (anti-CD45 Alexa
Fluor 700, no. 560566, BD Biosciences, 1:20; anti-CD3 PC7, no. 41116015,
Beckman Coulter, 1:20; anti-CD56 ECD, no. 41116015, Beckman Coulter,
1:40; anti-CD16 PerCP-Cy5.5, no. 560717, BD Biosciences, 1:20).
CD107a Degranulation and Intracellular IFN-g
After 4 hr activation by target cells, NK cells were stained with anti-CD107a
(FITC; no. 555800; BD Biosciences; 1:10), -CD3, -CD45, -CD56, and -CD16
antibodies. Intracellular IFN-g expression was assessed with APC-conjugated
anti-IFN-g antibody (no. 130-097-944; Miltenyi; 1:25) after cell fixation (PFA)
and permeabilization (PBS + BSA 0.2% + saponine 0.1% buffer, for 30 min
at room temperature). NK degranulation and IFN-g expression were quantified
within the CD45+CD3CD56+CD16+/ cell population. NK cells without target
tumor cells were used as a control.
Inhibitors/Stimulatory Molecules
Inhibitors
Human anti-IL-6 antibody (MAB206; clone no. 6708; R&D) was added at the
final concentration of 2 mg/mL at the start of co-culture. Inhibition of PGE2
was achieved using NS-398 (no. 70590; Cayman Chemical) at the final con-
centration of 5 mM. Medium + DMSO or + PBS were used as negative controls
for NS-398 and IL-6 treatment, respectively.
NK Stimulation
Human recombinant IL-6 (SRP3096; Sigma) was used at a final concentration
of 25 ng/mL. PGE2 was obtained from Sigma (P0409) and used at 1 mM
(350 ng/mL). Medium + EtOH was used as a negative control. NK cells were
treated for 4 days.
ELISA
IFN-g ELISA (Human IFN-g DuoSet ELISA; no. DY285-05; R&D) was
performed on MSC/NK/K562 and MSC/NK/PCC co-culture supernatants,
according to the manufacturer’s instructions. Controls for baseline IFN-g
secretion were supernatants from NK cells alone and NK cells cultured with
K562 cells. Samples were diluted 2-fold and analyzed in duplicates.
Quantification of IL-6 secretion by MSCs was performed by ELISA (Human
IL-6 DuoSet ELISA; no. DY206-05; R&D) in culture supernatants, according to
the manufacturer’s instructions. Samples were diluted 4- to 8-fold.
PGE2 was quantified using the Prostaglandin E2 Parameter Assay Kit
(no. KGE004B; R&D) according to the manufacturer’s protocol. Samples
were diluted 3- to 7-fold.
IFN-g, TNFa, HGF, IL-6, and TGFb1 were assessed in the co-culture super-
natants by Luminex assay (Bio-Plex Pro Human Cytokine/TGFb; Bio-Rad).
RNA Extraction, cDNA Synthesis, and qRT-PCR
Total RNA was extracted from MSCs using the RNeasy mini Kit (QIAGEN),
following standard procedures. cDNA was synthesized by reverse transcrip-
tion using M-MLV Reverse Transcriptase (Promega) according to the manu-
facturer’s instructions. qRT-PCR amplification was performed using TaqMan
Universal PCR mastermix or SYBR Green mix (Applied Biosystems). Samples
were analyzed in triplicates (37.5 ng of cDNA/reaction). Data were analyzed by
the 2DDCt method, normalizing threshold cycles first to housekeeping gene
expression (PPIA [protein phosphatase 1; TaqMan probe; Hs99999904_m1],
GAPDH [SYBR Green], or TBP [SYBR Green]) and then to controls. Primers
were purchased from Microsynth AG (see Supplemental Experimental
Procedures).
Statistics
Wilcoxon matched-pairs signed rank test was used for nonparametric data
and for comparing twomatched groups (N- and T-MSCs). Multiple group anal-
ysis was performed by 2-way ANOVA test followed by Tukey’s multiple
comparisons test or Dunnett’s multiple comparisons test for nonparametric
data. Statistical significance (adjusted p value) of the comparison between
BM-MSCs and lung tissue MSCs was determined by an unpaired t test with
Welch’s correction. For qRT-PCR data, multiple t tests corrected for multiple
comparisons using the Holm-Sidak method were used to compare mean
expression levels between N- and T-MSCs for each patient. For correlation
analysis, the Spearman test was used with the correlation coefficient r. Figures
also showed linear regression line with R2 for the goodness of fit. Calculations
were performed in Prism 7 (GraphPad Software). p values < 0.05 were consid-
ered statistically significant and are denoted by asterisks: *p < 0.05; **p < 0.01;
***p < 0.001; ns, not significant. Error bars represent the SEM, unless stated
otherwise.
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